Chugai News Releases are issued to provide stakeholders with the most up-to-date information related to our company. In some instances, information on products or drug candidates under development may be included, but this is intended for members of the media, shareholders, and investors. The information is not intended for promotional or advertising purposes, or as medical advice, etc.

Oct 31, 2018

Withdrawal of Lawsuits and Petitions for Provisional Disposition Order

Name of listed company: Chugai Pharmaceutical Co., Ltd.
Code number: 4519 (1st Section of Tokyo Stock Exchange)
Head office: 1-1, Nihonbashi-Muromachi 2-Chome, Chuo-ku, Tokyo
President & CEO: Tatsuro Kosaka
Inquiries to: Masahiko Uchida,
General Manager, Corporate Communications Dept.

October 31, 2018 (Tokyo) -- Chugai Pharmaceutical Co., Ltd. announced that it has decided to withdraw its lawsuits and petitions for provisional disposition order which have been filed independently against Daiichi Sankyo Co., Ltd. and Pfizer Japan Inc.

Chugai has filed two lawsuits to the Tokyo District Court as of October 12, and has also filed two petitions for provisional disposition order, demanding the suspension of manufacturing and distribution of the biosimilar of anti-HER2 monoclonal antibody Herceptin® Injection 60 and 150 (Herceptin® Injection), against Daiichi Sankyo Co., Ltd. and Pfizer Japan Inc., the marketing authorization holders of the biosimilar of Herceptin® Injection, citing such party’s infringement of the application patent owned by Genentech, a member of the Roche group, as the ground.

Herceptin® Injection is an anti-cancer agent, using anti-HER2 monoclonal antibody trastuzumab (genetical recombination), which Genentech has created. Herceptin® Injection is indicated for the treatment of breast cancer that overexpresses HER2, and advanced or recurrent gastric cancer overexpressing HER2 not amenable to curative resection.

As a company that aims to provide innovative drugs, we regard intellectual property rights that protect products and technologies resulted from research and development as a very important asset. Chugai will deal rigorously with any acts that violate them, including taking legal actions.

There is no impact on Chugai’s financial prospects for this matter at this stage.

Trademarks used or mentioned in this release are protected by law.


  • For Media
  • Chugai Pharmaceutical Co., Ltd.
  • Media Relations Group, Corporate Communications Dept.,
  • Tomoko Shimizu
  • Tel: +81-3-3273-0881
  • E-mail:
  • For Investors
  • Chugai Pharmaceutical Co., Ltd.
  • Investor Relations Group, Corporate Communications Dept.,
  • Toshiya Sasai
  • Tel: +81-3-3273-0554
  • E-mail:
  • Like
  • Post
  • LINE it!
  • E-mail
Back to top